ClinicalTrials.gg
Sign In

Hyperparathyroidism, Secondary clinical trials

The registry lists 188 studies for Hyperparathyroidism, Secondary across more than 10 countries. 15 are recruiting or about to start. 122 of them are mainly about Hyperparathyroidism, Secondary (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05. Counting its narrower condition Chronic Kidney Disease-Mineral and Bone Disorder too: 246 studies, 33 open.

Get an email when these change. Save the Hyperparathyroidism, Secondary studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
139
Terminated
16
Status unknown
12
Recruiting
10
Not yet recruiting
5
Withdrawn
4

Phase

Phase 3
45
Phase 4
43
Phase 2
31
Phase 1
17

Where

United States
66
China
23
Germany
16
Poland
15
Spain
15
Italy
15

Who runs them

Amgen (33) · Abbott (13) · AbbVie (prior sponsor, Abbott) (12) · OPKO Health, Inc. (8) · Kyowa Kirin Co., Ltd. (7) · OPKO IP Holdings II, Inc. (5) · KAI Pharmaceuticals (5) · Shanghai Hengrui Pharmaceutical Co., Ltd. (5)

What is being tested here

Drugs under test in Hyperparathyroidism, Secondary studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Etelcalcetide2916
MT1013213
Modified-release Calcifediol Capsule148
Calcifediol148
Upacicalcet155
Upacicalcet sodium hydrate133
Paricalcitol0629
Cinacalcet0828
1 alpha-hydroxyergocalciferol008
Evocalcet046

Coming up

4phase 3 studies under way
5studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5, phase 3 first

Who these studies take

Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger. 4 (40%) take children under 18. 1 (10%) are for women only and 0 (0%) for men only; 1 (10%) take healthy volunteers.

Recruiting studies that take each age, of 10
AgeWomenMen
104 (40%)4 (40%)
187 (70%)6 (60%)
307 (70%)6 (60%)
407 (70%)6 (60%)
507 (70%)6 (60%)
657 (70%)6 (60%)
756 (60%)5 (50%)
855 (50%)5 (50%)

Across all 188 studies, recruiting or not: 21% stop at 75 or younger and 13% at 65; 14% take children; 2% are for women only and 1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hyperparathyroidism, Secondary studies take

Of 21 phase 3 interventional studies under Hyperparathyroidism, Secondary, half reached primary completion within 22 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 322 mo14–31 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 188. Browse all 188 → or search them.